Congratulations to SCS researchers Professor Peter Ebeling and Associate Professor Rebecca Lim who have been recognised in The Australian’s Research 2020 magazine. Read more here.
Featured post
SCS research and awards news
For all our research and awards news, please visit our news page.
Showing posts with label peter ebeling. Show all posts
Showing posts with label peter ebeling. Show all posts
Monday, 5 October 2020
Wednesday, 26 August 2020
Congratulations to Professor Peter Ebeling AO - newly appointed President-Elect of ASBMR
Congratulations to Professor Peter Ebeling AO, Head of the Department of Medicine in the School of Clinical Sciences at Monash Health, as he was recently announced President-Elect of the American Society for Bone and Mineral Research (ASBMR).
This is a massive milestone as Professor Peter Ebeling is the first President to be elected outside of North America.
Read the full story HERE
Tuesday, 28 July 2020
$1.39 million MRFF grant for research on falls and fragility fractures
![]() |
| L-R: Prof Peter Ebeling, A/Prof David Scott |
Thursday, 21 May 2020
NHMRC & MRFF Investigator Grant success for SCS
NHMRC Investigator grants were announced yesterday 20 May 2020 by Federal Health Minister, The Honourable Greg Hunt MP. Congratulations to the School of Clinical Sciences at Monash Health (SCS) NHMRC & MRFF Investigator grant recipients! See more about the SCS projects, below. SCS has received over $7.5m across the period 2021-2025.Wednesday, 16 October 2019
Professor Peter Ebeling AO presented prestigious Boy Frame Award
Monday, 29 October 2018
Monash University’s Professor Peter Ebeling raises awareness of bone health for World Osteoporosis Day
Monday, 3 September 2018
Publications week ending 31 August 2018
MANAGEMENT OF ENDOCRINE DISEASE: Therapeutics of Vitamin D. Peter Ebeling et al. published in the European Journal of Endocrinology.
Heritable methylation marks associated with breast and prostate cancer risk. Melissa Southey et al. published in The Prostate.
Interprofessional education and practice guide No. 9: Sustaining interprofessional simulation using change management principles. Arunaz Kumar et al. published in The Journal of Interprofessional Care.
Behavioral and neurodevelopmental outcome of children after maternal allopurinol administration during suspected fetal hypoxia: 5-year follow up of the ALLO-trial. Ben Mol et al. published in PLoS One.
Heritable methylation marks associated with breast and prostate cancer risk. Melissa Southey et al. published in The Prostate.
Interprofessional education and practice guide No. 9: Sustaining interprofessional simulation using change management principles. Arunaz Kumar et al. published in The Journal of Interprofessional Care.
Behavioral and neurodevelopmental outcome of children after maternal allopurinol administration during suspected fetal hypoxia: 5-year follow up of the ALLO-trial. Ben Mol et al. published in PLoS One.
Monday, 18 June 2018
Fracture risk in young and middle-aged adults with Type 1 diabetes mellitus: a systematic review and meta-analysis
Helena Teede et al. published in Clinical Endocrinology.
Monday, 11 June 2018
Monday, 4 June 2018
Monday, 28 May 2018
Sex hormone-binding globulin is a biomarker associated with nonvertebral fracture in men on dialysis therapy
Monday, 21 May 2018
Monday, 14 May 2018
Monday, 16 April 2018
Monday, 12 March 2018
Cutting edge bone imaging at Monash University - an Australian first
![]() |
| Ms Barbara Yeoh, Chair Monash Health, Professor Peter Ebeling and Dr Ayse Zengin in front of the XtremeCT-II scanner at MHTP |
The XtremeCT-II high resolution peripheral quantitative computed
tomography was purchased with funds from the National Health and Medical
Research Council, Monash University and the Ian Potter Foundation.
Research fellow Dr Ayse Zengin said the XtremeCT-II measures 3D
bone microstructure, tendons, cartilage, joints, muscle, fat and vascular
calcification at the highest resolution and precision currently available.
“The XtremeCT-II is the only one of its kind in Australia
and will allow cutting edge musculoskeletal research both domestically and
internationally,” Dr Zengin said.
The XtremeCT-II will be available as a research platform for
researchers, clinicians and surgeons—ensuring collaboration amongst health care
professionals.
Subscribe to:
Posts (Atom)





